

Anti-GPRC5D & CD3 Reference Antibody (Talquetamab)

Catalog # APR11577

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9NZD1 & P07766
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information


Target/Specificity	CD3,GPRC5D / GPC5D
Expression system	CHO

Protein Information

Images








Anti-GPRC5D & CD3 Reference Antibody (Talquetamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti-GPRC5D & CD3 Reference Antibody (Talquetamab) is more than 97.10%, determined by SEC-HPLC.

Talquetamab bound to GPRC5D protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Talquetamab bound to hu-GPRC5D-VLP, and the EC50 was 0.978 nM.



Talquetamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Talquetamab bound to huCD3e-jurkat cells, and the EC50 was 6.175 nM.

Talquetamab bound to huGPRC5D-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig 3, Talquetamab bound to huGPRC5D-HEK293 cells, and the EC50 was 2.067 nM.

Plated and cultivated Talquetamab at 4°C overnight, then with the addition of NF-AT-Jurkat cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Talquetamab was able to activate the NF-AT signaling pathway, and the EC50 was 7.499 nM.

The detected molecular weight of Anti-GPRC5D & CD3 Reference Antibody (Talquetamab) is 144.32 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.